Delivery Order SPE2DB22D2006-SPE2DB25FV7XN
Award Date
1/28/25
Potential Completion Date
1/29/25
Potential Value
$84K
Federal Agency
Defense Logistics Agency
Awardee
Amerisourcebergen Drug Corp
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,527.44 Firm Fixed Price Delivery Order contract is for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a vaccine product. The contract has an ultimate completion date of January 31, 2025 and was awarded on January 30, 2025. There was no set-aside designation for this contract. AmerisourceBergen also holds a...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp's Corporate Office Division, a major supplier of pharmaceutical products and medical supplies to the U.S. government. The award, valued at $1,971.60, is a Delivery Order contract for the provision of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product. The contract has a Firm Fixed Price pricing type and an ultimate completion date of May 8, 2024. Amerisourcebergen holds a...
This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract award, valued at $87,982.50, is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a specific pharmaceutical product. The contract is a delivery order under an Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA Troop Support Medical. This IDC,...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $44,952.48 firm fixed-price delivery order contract is for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a hepatitis B vaccine. The contract has an ultimate completion date of May 22, 2024. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
This is a federal contract award issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML. The contract has a firm fixed price of $1,263.72 and a completion date of January 7, 2025. It is a delivery order contract, not associated with a larger contract vehicle. The award does not have a set-aside designation, indicating open competition. As a major supplier of pharmaceutical products...
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, was issued by the Defense Logistics Agency (DLA) for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a vaccine product. The $18,927.36 firm fixed price delivery order has a completion date of July 12, 2024. This award is a part of a larger $999,999,999 Indefinite Delivery Contract between Amerisourcebergen and the DLA Troop Support Medical, which provides a comprehensive range of pharmaceutical...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a subsidiary of the global pharmaceutical distribution company AmerisourceBergen Corporation. The $1,577.28 firm fixed price delivery order is for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a specialty pharmaceutical product, to support military treatment programs and facilities. AmerisourceBergen Drug Corp holds an indefinite delivery contract (IDC) with DLA, valued at up to...
The U.S. Defense Logistics Agency (DLA) has awarded a Delivery Order contract worth $2,365.92 to Amerisourcebergen Drug Corp's Corporate Office Division. The contract is for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product. This Delivery Order is issued under Amerisourcebergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at up to $999,999,999.00 through December 31, 2025. The IDC enables DLA to efficiently procure essential...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $25,236.48 Firm Fixed Price Delivery Order is for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a vaccine product. The award does not have any set-aside designation, indicating open competition. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This federal contract award, valued at $23,659.20, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is a Delivery Order under an existing Indefinite Delivery Contract (IDC) with the DLA, valued at up to $999,999,999.00 and running through November 2026. The contract covers the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product, to support military treatment...